SinuSys developed and is marketing a maxillary sinus dilator for the treatment of chronic sinusitis, a condition that affects more than 37 million Americans. The standard course of treatment is currently antibiotics for sinus infections, a balloon dilation system or surgery. The Vent-OS Sinus Dilation system offers a less invasive alternative to surgery. It was U.S. FDA cleared for diagnostic and therapeutic procedures in January 2014 and is on the market.
For more information, visit www.sinusys.com.
Heart Metabolics is in pharmaceutical research and development for a drug to treat hypertrophic cardiomyopathy, the most common hereditary cause of cardiomyopathy, which is the leading cause of sudden death in young people. The medication for MCM, perhexilene, received an Orphan Drug Designation from by the U.S. FDA.
For more information, visit www.heartmetabolics.com.
Armetheon is a pharmaceutical research and development company working on multiple medications, including antibiotics for resistant bacteria, anticoagulants, anti-arrhythmic and an anti-GERD drug. The company’s work on antibiotics is a critical contribution to the future of medicine as the potential obsolescence of antibiotics poses a health risk for patients all over the world. Likewise, the company is developing medications to serve as alternatives to existing drugs that may provide fewer side effects and/or more predictable results for patients than their current counterparts.
For more information, visit www.armetheon.com.